Table of Contents
<< Previous Issue | Dec 2012 (Vol: 2012, Issue: 12) | Next Issue >> |
- Section: Joint Venture
-
Nestlé and Chi-Med Form Joint Venture to Develop Drugs Based on Traditional Chinese Medicine
- Section: Licensing
-
Teva Licenses Xenon Pharmaceuticals’ Pain Drug XEN402 as Part of New Strategic Plan
-
Isis Pharmaceuticals Ends 2012 with an Antisense Cancer Alliance with AstraZeneca
- Section: Mergers & Acquisitions
-
Wright Medical Bets on BioMimetic Therapeutics with Merger Agreement
-
Reckitt Benckiser Ventures into Vitamins, Minerals and Supplements Market with Schiff Nutrition Purchase
-
BASF Aims for Top Spot in Omega-3 API Market with Pronova BioPharma Acquisition
-
Smith & Nephew Moves into Fast-Growing Bioactive Wound Care Segment with Healthpoint Biotherapeutics Acquisition
-
Amgen Makes Long-Term Investment in Targeted Therapies with deCODE Genetics Purchase
- Section: Research & Development
-
Selecta Biosciences Partners with Sanofi to Develop Antigen-Specific Immunotherapies for Allergies
-
Biogen Idec Signs Third Antisense Deal of 2012 with Isis Pharmaceuticals